Fabrication and Characterization of Ace Inhibitor Loaded Transdermal Patches
Corresponding Author(s) : Debasmita Ghosh
debasmitaghosh64@gmail.com
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 11 No. 2 (2023): 2023 Volume -11 - Issue 2
Abstract
The aim of the study is to formulate and evaluate transdermal patches of Captopril In the present study, matrix type was prepared by molding techniques. This mode of drug delivery is more beneficial for chronic disorders such hypertension and some types of congestive heart failure, which require long term drug administration to maintain therapeutic drug concentration in plasma. Transport of drugs or compounds via skin is a complex phenomenon, which allows the passage of drugs or compounds into and across the skin. In the present work an attempt has been made to formulate and evaluate the transdermal patches of Captopril using various blends of polymer. The polymeric Eudragit grade used for the formulation of transdermal patches showed good film forming property. The patches formed were thin, flexible, smooth and transparent. The weight variation tests showed less variation in weight and suggesting uniform distribution of drug and polymer over the mercury surface. The thicknesses of the transdermal patches were found to increase on increasing concentration of polymers. All the patches showed good flexibility and folding endurance properties. The result suggests that the formulations with increased polymer concentration showed long folding endurance. The in-vitro drug release studies showed that formulations F3 with increased concentration of polymer showed good release. The drug content analysis showed minimum variations suggesting uniform distribution of drug.
Keywords
Captopril
Transdermal drug delivery.
1.
Debasmita Ghosh, Mithun Bhowmick, Pratibha Bhowmick. Fabrication and Characterization of Ace Inhibitor Loaded Transdermal Patches. Int. J. of Allied Med. Sci. and Clin. Res. [Internet]. 2023 May 5 [cited 2026 Apr. 15];11(2):152-61. Available from: https://ijamscr.com/ijamscr/article/view/1319
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
References
-
1. Chien YW. Novel drug delivery systems. 2nd ed, Drugs And Pharmaceutical Sciences. Vol. 50. Marcel Dekker Inc.
2. Finnin BC, Morgan TM. Trasndermal penetration. J Pharm Sci. Oct 1999;88(10):955-8. doi: 10.1021/js990154g, PMID 10514338.
3. Allen LV, Popovich NG, Ansel HC. Ansel’s pharmaceutical dosage forms and drug delivery systems. 8th ed. Lippincott Williams & wilkins; 2005. p. 298-315.
4. Barry B. Transdermal drug delivery. In: Aulton ME, editor. Pharmaceutics: the science of dosage form design. Churchill Livingstone; 2002. p. 499-533.
5. Cleary GW. Transdermal controlled release systems. Med Appl Control Release;1:203-51.
6. Vyas SP, Khar RK. Controlled drug delivery: concepts and advances, Vallabh Prakashan. 1st ed; 2002. p. 411-47.
7. Tortora G, Grabowski S. The Integumentary system. In: Principles of anatomy and physiology. 9th ed. John Wiley & Sons Inc. p. 150-1.
8. Wilson KJW, Waugh A, editors. Ross and Wilson: anatomy and physiology in health and illness. 8th ed. Churchill Livingstone; 1996. p. 360-6.
9. Franz TJ. Transdermal delivery in treatise on controlled drug delivery. 3rd ed. New York: Marcel Dekker Inc; 1991.
10. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv. 2005;2(1):23-33. doi: 10.2174/1567201052772915, PMID 16305405.
11. Honeywell-Nguyen PL, Bouwstra JokeA. Vesicles as a tool for transdermal and Dermal Delivery. Drug Discov Today Technol. 2005;2(1):67-74. doi: 10.1016/j.ddtec.2005.05.003, PMID 24981757.
12. Gannu R, Vishnu YV, Kishan V, Rao YM. Development of nitrendipine transdermal patches: in vitro and ex-vivo characterization. Curr Drug Deliv. 2007;4(1):69-76. doi: 10.2174/156720107779314767, PMID 17269919.
13. Gupta JRD, Irchiayya RN.Garud. Formulation and evaluation of matrix type transdermal patches of glibenclamide. Int J Pharm Sci Dev Res. 2009;1(1):46-50.
14. Walters KA, Roberts ms. Dermatological and transdermal formulations. p. 204-41.
15. Oh SY, Jeong SY, Park TG, Lee JH. Enhanced transdermal delivery of AZT (zidovudine) using iontophoresis and penetration enhancer. J Control Release. 1998 Feb 12;51(2-3):161-8. doi: 10.1016/s0168-3659(97)00162-4, PMID 9685913.
References
1. Chien YW. Novel drug delivery systems. 2nd ed, Drugs And Pharmaceutical Sciences. Vol. 50. Marcel Dekker Inc.
2. Finnin BC, Morgan TM. Trasndermal penetration. J Pharm Sci. Oct 1999;88(10):955-8. doi: 10.1021/js990154g, PMID 10514338.
3. Allen LV, Popovich NG, Ansel HC. Ansel’s pharmaceutical dosage forms and drug delivery systems. 8th ed. Lippincott Williams & wilkins; 2005. p. 298-315.
4. Barry B. Transdermal drug delivery. In: Aulton ME, editor. Pharmaceutics: the science of dosage form design. Churchill Livingstone; 2002. p. 499-533.
5. Cleary GW. Transdermal controlled release systems. Med Appl Control Release;1:203-51.
6. Vyas SP, Khar RK. Controlled drug delivery: concepts and advances, Vallabh Prakashan. 1st ed; 2002. p. 411-47.
7. Tortora G, Grabowski S. The Integumentary system. In: Principles of anatomy and physiology. 9th ed. John Wiley & Sons Inc. p. 150-1.
8. Wilson KJW, Waugh A, editors. Ross and Wilson: anatomy and physiology in health and illness. 8th ed. Churchill Livingstone; 1996. p. 360-6.
9. Franz TJ. Transdermal delivery in treatise on controlled drug delivery. 3rd ed. New York: Marcel Dekker Inc; 1991.
10. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv. 2005;2(1):23-33. doi: 10.2174/1567201052772915, PMID 16305405.
11. Honeywell-Nguyen PL, Bouwstra JokeA. Vesicles as a tool for transdermal and Dermal Delivery. Drug Discov Today Technol. 2005;2(1):67-74. doi: 10.1016/j.ddtec.2005.05.003, PMID 24981757.
12. Gannu R, Vishnu YV, Kishan V, Rao YM. Development of nitrendipine transdermal patches: in vitro and ex-vivo characterization. Curr Drug Deliv. 2007;4(1):69-76. doi: 10.2174/156720107779314767, PMID 17269919.
13. Gupta JRD, Irchiayya RN.Garud. Formulation and evaluation of matrix type transdermal patches of glibenclamide. Int J Pharm Sci Dev Res. 2009;1(1):46-50.
14. Walters KA, Roberts ms. Dermatological and transdermal formulations. p. 204-41.
15. Oh SY, Jeong SY, Park TG, Lee JH. Enhanced transdermal delivery of AZT (zidovudine) using iontophoresis and penetration enhancer. J Control Release. 1998 Feb 12;51(2-3):161-8. doi: 10.1016/s0168-3659(97)00162-4, PMID 9685913.
2. Finnin BC, Morgan TM. Trasndermal penetration. J Pharm Sci. Oct 1999;88(10):955-8. doi: 10.1021/js990154g, PMID 10514338.
3. Allen LV, Popovich NG, Ansel HC. Ansel’s pharmaceutical dosage forms and drug delivery systems. 8th ed. Lippincott Williams & wilkins; 2005. p. 298-315.
4. Barry B. Transdermal drug delivery. In: Aulton ME, editor. Pharmaceutics: the science of dosage form design. Churchill Livingstone; 2002. p. 499-533.
5. Cleary GW. Transdermal controlled release systems. Med Appl Control Release;1:203-51.
6. Vyas SP, Khar RK. Controlled drug delivery: concepts and advances, Vallabh Prakashan. 1st ed; 2002. p. 411-47.
7. Tortora G, Grabowski S. The Integumentary system. In: Principles of anatomy and physiology. 9th ed. John Wiley & Sons Inc. p. 150-1.
8. Wilson KJW, Waugh A, editors. Ross and Wilson: anatomy and physiology in health and illness. 8th ed. Churchill Livingstone; 1996. p. 360-6.
9. Franz TJ. Transdermal delivery in treatise on controlled drug delivery. 3rd ed. New York: Marcel Dekker Inc; 1991.
10. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv. 2005;2(1):23-33. doi: 10.2174/1567201052772915, PMID 16305405.
11. Honeywell-Nguyen PL, Bouwstra JokeA. Vesicles as a tool for transdermal and Dermal Delivery. Drug Discov Today Technol. 2005;2(1):67-74. doi: 10.1016/j.ddtec.2005.05.003, PMID 24981757.
12. Gannu R, Vishnu YV, Kishan V, Rao YM. Development of nitrendipine transdermal patches: in vitro and ex-vivo characterization. Curr Drug Deliv. 2007;4(1):69-76. doi: 10.2174/156720107779314767, PMID 17269919.
13. Gupta JRD, Irchiayya RN.Garud. Formulation and evaluation of matrix type transdermal patches of glibenclamide. Int J Pharm Sci Dev Res. 2009;1(1):46-50.
14. Walters KA, Roberts ms. Dermatological and transdermal formulations. p. 204-41.
15. Oh SY, Jeong SY, Park TG, Lee JH. Enhanced transdermal delivery of AZT (zidovudine) using iontophoresis and penetration enhancer. J Control Release. 1998 Feb 12;51(2-3):161-8. doi: 10.1016/s0168-3659(97)00162-4, PMID 9685913.